Immunotherapy for Epstein Barr Virus-Associated Cancers in Children

Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children Karin C.M. Straathof, Catherine M. Bollard, Cliona M. Rooney, Helen E. Heslop Oncologist 2003; 8: 83-98 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in pediatric oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the pathogenesis of post-transplant lymphoproliferative disease. Identify patients at risk for post-transplant lymphoproliferative disease. Appreciate the rationale for using immunotherapy approaches in Epstein-Barr virus-associated malignancies. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Feb. 24, 2003 Most Recent Review: Feb. 24, 2003* Most Recent Update: Feb. 24, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.